Published in J Natl Cancer Inst on January 03, 2007
Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2012) 3.72
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut (2015) 2.19
Economic aspects of bladder cancer: what are the benefits and costs? World J Urol (2009) 1.98
Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Complementary and alternative medicine provider use and expenditures by cancer treatment phase. Am J Manag Care (2008) 1.51
Evaluation of record linkage between a large healthcare provider and the Utah Population Database. J Am Med Inform Assoc (2011) 1.35
Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) (2013) 1.33
Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist (2012) 1.25
Evaluating the cost-effectiveness of cancer patient navigation programs: conceptual and practical issues. Cancer (2009) 1.24
The out of pocket cost of breast cancer survivors: a review. J Cancer Surviv (2010) 1.19
Time costs of fertility care: the hidden hardship of building a family. Fertil Steril (2013) 1.13
Does economic burden influence quality of life in breast cancer survivors? Gynecol Oncol (2011) 1.13
The association of depression and pain with health-related quality of life, disability, and health care use in cancer patients. J Pain Symptom Manage (2010) 1.12
Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat (2010) 1.07
State-level projections of cancer-related medical care costs: 2010 to 2020. Am J Manag Care (2012) 1.06
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med (2012) 1.03
Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer (2010) 1.01
Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc (2010) 1.00
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer (2009) 0.99
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? J Rural Health (2011) 0.93
Inter-relationships between the economic and emotional consequences of colorectal cancer for patients and their families: a qualitative study. BMC Gastroenterol (2012) 0.93
Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst Monogr (2013) 0.88
Annual patient time costs associated with medical care among cancer survivors in the United States. Med Care (2014) 0.86
Healthcare utilization in women after abdominal surgery for ovarian cancer. Nurs Res (2010) 0.86
Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. J Gastric Cancer (2015) 0.86
End-of-life planning and its relevance for patients' and oncologists' decisions in choosing cancer therapy. Cancer (2008) 0.86
Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol (2011) 0.85
Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer. Front Oncol (2015) 0.84
Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int (2015) 0.82
The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics (2014) 0.82
Therapy choices and quality of life in young breast cancer survivors: a short-term follow-up. Am J Surg (2013) 0.81
Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. J Natl Cancer Inst (2015) 0.81
Financial toxicity: a potential side effect of prostate cancer treatment among Australian men. Eur J Cancer Care (Engl) (2015) 0.80
How much does it cost to care for survivors of colorectal cancer? Caregiver's time, travel and out-of-pocket costs. Support Care Cancer (2013) 0.79
The Economic Burden of Breast Cancer in Iran. Iran J Public Health (2015) 0.79
State-level cancer treatment costs: how much and who pays? Cancer (2013) 0.79
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. Support Care Cancer (2013) 0.79
Does value mean quality? The payer's perspective. J Oncol Pract (2013) 0.78
Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina. Health Serv Res (2014) 0.78
The forest and the trees: the human costs of cancer. J Natl Cancer Inst (2007) 0.77
Inequalities in access to cancer treatment: an analysis of cross-regional patient mobility in Greece. Support Care Cancer (2011) 0.75
Measuring the use of examination room time in oncology clinics: a novel approach to assessing clinic efficiency and patient flow. J Oncol Pract (2014) 0.75
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst (2002) 6.64
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Utility of the SEER-Medicare data to identify chemotherapy use. Med Care (2002) 5.07
Assessing comorbidity using claims data: an overview. Med Care (2002) 4.94
Tumor boards and the quality of cancer care. J Natl Cancer Inst (2012) 4.87
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol (2007) 4.81
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med (2004) 4.49
Use of SEER-Medicare data for measuring cancer surgery. Med Care (2002) 4.27
Studying radiation therapy using SEER-Medicare-linked data. Med Care (2002) 4.13
An overview of methods for monitoring social disparities in cancer with an example using trends in lung cancer incidence by area-socioeconomic position and race-ethnicity, 1992-2004. Am J Epidemiol (2008) 3.86
Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst (2004) 3.74
Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care (2002) 3.57
Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. Med Care (2005) 3.53
Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med (2009) 3.34
Health plan policies and programs for colorectal cancer screening: a national profile. Am J Manag Care (2004) 3.27
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care (2006) 3.08
Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol (2012) 2.77
Surveying physicians: do components of the "Total Design Approach" to optimizing survey response rates apply to physicians? Med Care (2002) 2.68
Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol (2005) 2.67
Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med (2009) 2.67
Current and future utilization of services from medical oncologists. J Clin Oncol (2008) 2.65
Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev (2009) 2.46
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Barriers to colorectal cancer screening among Medicare consumers. Am J Prev Med (2006) 2.31
Identifying cancer relapse using SEER-Medicare data. Med Care (2002) 2.28
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst (2009) 2.20
Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol (2002) 2.12
Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst (2005) 2.08
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
Data sources for measuring colorectal endoscopy use among Medicare enrollees. Cancer Epidemiol Biomarkers Prev (2007) 2.02
End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. Cancer (2010) 2.01
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
Estimating patient time costs associated with colorectal cancer care. Med Care (2005) 1.94
A national framework for cancer surveillance in the United States. Cancer Causes Control (2005) 1.89
Improving the quality of surveys of physicians and medical groups: a research agenda. Eval Health Prof (2012) 1.84
Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst (2008) 1.84
Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst (2008) 1.83
Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care (2009) 1.76
Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ (2008) 1.72
Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study. Med Care (2005) 1.71
Area-level variations in cancer care and outcomes. Med Care (2012) 1.68
Trends in colorectal cancer test use in the medicare population, 1998-2005. Am J Prev Med (2009) 1.68
Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol (2002) 1.63
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62
Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology (2012) 1.62
Another round in the mammography controversy. J Womens Health (Larchmt) (2003) 1.62
Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol (2011) 1.59
Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev (2008) 1.59
Overview of the SEER--Medicare Health Outcomes Survey linked dataset. Health Care Financ Rev (2008) 1.55
Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol (2007) 1.54
Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology (2009) 1.52
Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol (2002) 1.52
Are physicians' recommendations for colorectal cancer screening guideline-consistent? J Gen Intern Med (2010) 1.44
External validation of a claims-based algorithm for classifying kidney-cancer surgeries. BMC Health Serv Res (2009) 1.40
Perceived ambiguity about screening mammography recommendations: association with future mammography uptake and perceptions. Cancer Epidemiol Biomarkers Prev (2007) 1.37
Measuring breast, colorectal, and prostate cancer screening with medicare claims data. Med Care (2002) 1.37
Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. Med Care (2002) 1.36
Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care (2013) 1.36
Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q (2012) 1.35
Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer Metastasis Rev (2003) 1.34
Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. Med Care (2004) 1.31
Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives. J Clin Oncol (2009) 1.30
Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer (2011) 1.30
Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol (2009) 1.28
Racial differences in the receipt of bowel surveillance following potentially curative colorectal cancer surgery. Health Serv Res (2003) 1.27
Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia. J Am Geriatr Soc (2004) 1.26
Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service. Cancer Epidemiol Biomarkers Prev (2008) 1.24
Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care (2014) 1.24